These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Alam MS; Getz M; Haldar K Sci Transl Med; 2016 Feb; 8(326):326ra23. PubMed ID: 26888431 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. Pipalia NH; Subramanian K; Mao S; Ralph H; Hutt DM; Scott SM; Balch WE; Maxfield FR J Lipid Res; 2017 Apr; 58(4):695-708. PubMed ID: 28193631 [TBL] [Abstract][Full Text] [Related]
4. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts. Newton J; Hait NC; Maceyka M; Colaco A; Maczis M; Wassif CA; Cougnoux A; Porter FD; Milstien S; Platt N; Platt FM; Spiegel S FASEB J; 2017 Apr; 31(4):1719-1730. PubMed ID: 28082351 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease. Subramanian K; Rauniyar N; Lavalleé-Adam M; Yates JR; Balch WE Mol Cell Proteomics; 2017 Nov; 16(11):1938-1957. PubMed ID: 28860124 [TBL] [Abstract][Full Text] [Related]
6. 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. Davidson J; Molitor E; Moores S; Gale SE; Subramanian K; Jiang X; Sidhu R; Kell P; Zhang J; Fujiwara H; Davidson C; Helquist P; Melancon BJ; Grigalunas M; Liu G; Salahi F; Wiest O; Xu X; Porter FD; Pipalia NH; Cruz DL; Holson EB; Schaffer JE; Walkley SU; Maxfield FR; Ory DS Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1545-1561. PubMed ID: 31051283 [TBL] [Abstract][Full Text] [Related]
7. An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. Munkacsi AB; Chen FW; Brinkman MA; Higaki K; Gutiérrez GD; Chaudhari J; Layer JV; Tong A; Bard M; Boone C; Ioannou YA; Sturley SL J Biol Chem; 2011 Jul; 286(27):23842-51. PubMed ID: 21489983 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Niemann--pick type C disease by histone deacetylase inhibitors. Helquist P; Maxfield FR; Wiech NL; Wiest O Neurotherapeutics; 2013 Oct; 10(4):688-97. PubMed ID: 24048860 [TBL] [Abstract][Full Text] [Related]
9. The potential of histone deacetylase inhibitors in Niemann - Pick type C disease. Maceyka M; Milstien S; Spiegel S FEBS J; 2013 Dec; 280(24):6367-72. PubMed ID: 23992240 [TBL] [Abstract][Full Text] [Related]
10. High-content screen for modifiers of Niemann-Pick type C disease in patient cells. Pugach EK; Feltes M; Kaufman RJ; Ory DS; Bang AG Hum Mol Genet; 2018 Jun; 27(12):2101-2112. PubMed ID: 29659804 [TBL] [Abstract][Full Text] [Related]
11. A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Maue RA; Burgess RW; Wang B; Wooley CM; Seburn KL; Vanier MT; Rogers MA; Chang CC; Chang TY; Harris BT; Graber DJ; Penatti CA; Porter DM; Szwergold BS; Henderson LP; Totenhagen JW; Trouard TP; Borbon IA; Erickson RP Hum Mol Genet; 2012 Feb; 21(4):730-50. PubMed ID: 22048958 [TBL] [Abstract][Full Text] [Related]
12. Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice. Alam MS; Cooper B; Farris JD; Haldar K Sci Rep; 2018 Mar; 8(1):3875. PubMed ID: 29497113 [TBL] [Abstract][Full Text] [Related]
14. Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid. Subramanian K; Hutt DM; Scott SM; Gupta V; Mao S; Balch WE J Biol Chem; 2020 Jun; 295(23):8017-8035. PubMed ID: 32354745 [TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of primidone in Niemann-Pick disease type C (NPC)-model cells and mice: Reduction of unesterified cholesterol levels in cells and extension of lifespan in mice. Ashikawa H; Mogi H; Honda T; Nakamura H; Murayama T Eur J Pharmacol; 2021 Apr; 896():173907. PubMed ID: 33503462 [TBL] [Abstract][Full Text] [Related]
16. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. Praggastis M; Tortelli B; Zhang J; Fujiwara H; Sidhu R; Chacko A; Chen Z; Chung C; Lieberman AP; Sikora J; Davidson C; Walkley SU; Pipalia NH; Maxfield FR; Schaffer JE; Ory DS J Neurosci; 2015 May; 35(21):8091-106. PubMed ID: 26019327 [TBL] [Abstract][Full Text] [Related]
17. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Ramirez CM; Liu B; Taylor AM; Repa JJ; Burns DK; Weinberg AG; Turley SD; Dietschy JM Pediatr Res; 2010 Oct; 68(4):309-15. PubMed ID: 20581737 [TBL] [Abstract][Full Text] [Related]
18. Decreased neural stem cell proliferation and olfaction in mouse models of Niemann-Pick C1 disease and the response to hydroxypropyl-β-cyclodextrin. Dragotto J; Palladino G; Canterini S; Caporali P; Patil R; Fiorenza MT; Erickson RP J Appl Genet; 2019 Nov; 60(3-4):357-365. PubMed ID: 31485950 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary abnormalities in animal models due to Niemann-Pick type C1 (NPC1) or C2 (NPC2) disease. Roszell BR; Tao JQ; Yu KJ; Gao L; Huang S; Ning Y; Feinstein SI; Vite CH; Bates SR PLoS One; 2013; 8(7):e67084. PubMed ID: 23843985 [TBL] [Abstract][Full Text] [Related]